Pharmacotherapy in patients with adenomyosis

K.R. Bakhtiyarov, И.В. Игнатко, А. В. Исаев, E.A. Samoilov
In: Voprosy ginekologii, akušerstva i perinatologii · 2024 · vol. 23(4) , pp. 102–106 · doi:10.20953/1726-1678-2024-4-102-106 · W4406903330
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-01 ⓘ

Dienogest effectively relieves adenomyosis symptoms like pain and bleeding, normalizes menstrual cycles, and reduces uterine volume, improving patient quality of life.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-07 · read from full text ⓘ

This literature review evaluates the efficacy of various hormonal pharmacotherapies for treating adenomyosis, with a specific focus on comparing dienogest against other standard treatments. The authors highlight that dienogest provides faster relief from pain syndrome and abnormal uterine bleeding compared to the levonorgestrel-releasing intrauterine system, while also demonstrating superior effectiveness in normalizing menstrual cycles relative to combined oral contraceptives. Additionally, the analysis notes that dienogest promotes a significant reduction in uterine volume and ovarian size, thereby improving overall patient quality of life. This paper is centrally about adenomyosis — specifically evaluating the comparative clinical benefits of dienogest as a primary hormonal treatment option.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

This article presents a literature review on the problem of pharmacotherapy for adenomyosis. A comparative analysis of the efficacy of various hormonal agents was performed. The article emphasizes the advantages of dienogest (Alvovizan), which effectively relieves clinical symptoms of adenomyosis such as dysmenorrhea, chronic pelvic pain, and heavy menstrual bleeding. Compared to levonorgestrel-releasing intrauterine system (LNG-IUS), dienogest significantly faster reduces the severity of pain syndrome and shortens the duration of abnormal uterine bleeding. Menstrual cycle normalization was noted with dienogest and combined oral contraceptives (COCs), but dienogest was more effective. In a comparative analysis of ovarian volumes, it was recorded that there was a significant decrease in ovarian size in both comparison groups. Conclusion. Dienogest (Alvovizan) is an effective medication for pain relief in adenomyosis. It promotes uterine volume reduction, which significantly improves the quality of life of patients. Abnormal uterine bleeding is effectively controlled by this medication. Key words: adenomyosis, dienogest, Alvovizan, combined oral contraceptives, levonorgestrel-releasing intrauterine system, gonadotropin-releasing hormone agonists
Full text 1,663 characters · extracted from oa-doi-fallback · click to expand
Pharmacotherapy in patients with adenomyosis Kamil R. Bakhtiyarov / Irina V. Ignatko / Abdurakhman K. Isaev / Evgenii A. Samoilov / This article presents a literature review on the problem of pharmacotherapy for adenomyosis. A comparative analysis of the efficacy of various hormonal agents was performed. The article emphasizes the advantages of dienogest (Alvovizan), which effectively relieves clinical symptoms of adenomyosis such as dysmenorrhea, chronic pelvic pain, and heavy menstrual bleeding. Compared to levonorgestrel-releasing intrauterine system (LNG-IUS), dienogest significantly faster reduces the severity of pain syndrome and shortens the duration of abnormal uterine bleeding. Menstrual cycle normalization was noted with dienogest and combined oral contraceptives (COCs), but dienogest was more effective. In a comparative analysis of ovarian volumes, it was recorded that there was a significant decrease in ovarian size in both comparison groups. Conclusion. Dienogest (Alvovizan) is an effective medication for pain relief in adenomyosis. It promotes uterine volume reduction, which significantly improves the quality of life of patients. Abnormal uterine bleeding is effectively controlled by this medication. Key words: adenomyosis, dienogest, Alvovizan, combined oral contraceptives, levonorgestrel-releasing intrauterine system, gonadotropin-releasing hormone agonists For citation: Bakhtiyarov K.R., Ignatko I.V., Isaev A.K., Samoilov E.A. Pharmacotherapy in patients with adenomyosis. Vopr. ginekol. akus. perinatol. (Gynecology, Obstetrics and Perinatology). 2024; 23(4): 102–106. (In Russian). DOI: 10.20953/1726-1678-2024-4-102-106

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosischronic_pelvic_paindysmenorrhea

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-09-27T06:17:51.937953+00:00
License: CC0 · commercial use OK